Core Viewpoint - After strategic adjustments, Taimei Medical Technology has achieved significant improvements in quality and efficiency, with core operating indicators showing positive trends and a return to accelerated growth in new orders, driven by the scaling of its AI strategy [2][4]. Financial Performance - In 2025, Taimei Medical Technology reported total revenue of 513 million RMB, a slight decrease of 7.0% year-on-year, primarily due to the company's strategic choice to optimize its revenue structure and reduce low-margin businesses [6]. - The gross margin improved to 42.4% in 2025, up 1.6 percentage points from 40.8% in 2024, indicating the effectiveness of the revenue structure optimization strategy [8]. - The annual loss significantly narrowed from 217 million RMB in 2024 to 50.7 million RMB in 2025, a reduction of 76.7%. The adjusted net loss was only 19.9 million RMB, a decrease of 73% year-on-year, exceeding market expectations [10]. Customer Base and Market Position - As of December 31, 2025, Taimei has served over 1,600 global pharmaceutical companies and CROs, participating in over 10,000 clinical development projects across 30 countries, solidifying its position as a leading provider of clinical development infrastructure solutions in China [12]. - Approximately 60% of Class 1 innovative drugs in China conducted clinical trials using Taimei's AI clinical development platform, and the company processes about 50% of adverse reaction reports in China [12]. AI Strategy and Platform Development - Taimei continues to strengthen its "AI for Success" strategy, focusing on addressing challenges in clinical development. The company has developed a comprehensive clinical development infrastructure covering clinical operations, data management, medical analysis, drug safety, and digital marketing [14]. - In 2025, Taimei achieved commercial breakthroughs in several AI modules, including AI agents for data science and drug safety, enhancing customer collaboration and operational efficiency [14]. Strategic Growth Engines - Looking ahead to 2026 and beyond, Taimei plans to focus on three strategic directions: expanding AI agent coverage across key R&D processes, accelerating international expansion in markets like the US, Singapore, Japan, South Korea, and Australia, and gradually advancing its innovative drug rights platform [16].
太美医疗科技2025年新签订单增36%，AI战略规模化落地成核心驱动力